← Back to Discover
BB BIOTECH AG
Period ended Mar 31, 2019 · Latest filing May 13, 2019
These quarterly holdings are delayed and may not include all assets or short positions.
Values are from the reporting date, not current prices or purchase costs.
The same security may appear in multiple rows.
Source: SEC
Reported portfolio value
Quarter-end reported holdings; not current value or investment performance.
View reported values
- Mar 31, 2019: $3,977,857,000
More quarters will appear as history becomes available.
Top holdings
Top 10 at Mar 31, 2019. Matching entries are combined; security classes and options remain separate. Shares exclude principal amounts; option shares reflect the reported underlying amount.
View top holdings values
- Ionis Pharmaceuticals Inc. · COM · 462222100 · shares: $627,038,000
- Incyte Corp. · COM · 45337C102 · shares: $311,356,000
- Neurocrine Biosciences Inc. · COM · 64125C109 · shares: $296,614,000
- Vertex Pharmaceuticals Inc · COM · 92532F100 · shares: $239,135,000
- Sage Therapeutics, Inc. · COM · 78667J108 · shares: $218,730,000
- Celgene Corp · COM · 151020104 · shares: $207,548,000
- Agios Pharmaceuticals, Inc. · COM · 00847X104 · shares: $200,845,000
- Alexion Pharmaceuticals, Inc. · COM · 015351109 · shares: $177,684,000
- Alnylam Pharmaceuticals, Inc. · COM · 02043Q107 · shares: $152,425,000
- Esperion Therapeutics, Inc. · COM · 29664W105 · shares: $141,447,000
Reported holdings
35 reported entries| Issuer | Class | CUSIP | Type | Shares / principal | Reported value (USD) |
|---|---|---|---|---|---|
| Ionis Pharmaceuticals Inc. | COM | 462222100 | — | 7,725,000 shares | $627,038,000 |
| Incyte Corp. | COM | 45337C102 | — | 3,620,000 shares | $311,356,000 |
| Neurocrine Biosciences Inc. | COM | 64125C109 | — | 3,366,786 shares | $296,614,000 |
| Vertex Pharmaceuticals Inc | COM | 92532F100 | — | 1,300,000 shares | $239,135,000 |
| Sage Therapeutics, Inc. | COM | 78667J108 | — | 1,375,229 shares | $218,730,000 |
| Celgene Corp | COM | 151020104 | — | 2,200,000 shares | $207,548,000 |
| Agios Pharmaceuticals, Inc. | COM | 00847X104 | — | 2,978,134 shares | $200,845,000 |
| Alexion Pharmaceuticals, Inc. | COM | 015351109 | — | 1,314,428 shares | $177,684,000 |
| Alnylam Pharmaceuticals, Inc. | COM | 02043Q107 | — | 1,631,089 shares | $152,425,000 |
| Esperion Therapeutics, Inc. | COM | 29664W105 | — | 3,522,964 shares | $141,447,000 |
| Radius Health, Inc. | COM NEW | 750469207 | — | 6,781,685 shares | $135,227,000 |
| Halozyme Therapeutics Inc. | COM | 40637H109 | — | 8,322,860 shares | $133,998,000 |
| Argenx SE | SPONSORED ADR | 04016X101 | — | 904,739 shares | $112,948,000 |
| Moderna, Inc. | COM | 60770K107 | — | 4,785,681 shares | $97,389,000 |
| Myovant Sciences Ltd. | COM | G637AM102 | — | 3,597,882 shares | $85,881,000 |
| Intercept Pharmaceuticals, Inc. | COM | 45845P108 | — | 696,976 shares | $77,964,000 |
| Gilead Sciences Inc. | COM | 375558103 | — | 1,142,204 shares | $74,255,000 |
| Nektar Therapeutics | COM | 640268108 | — | 2,020,676 shares | $67,895,000 |
| Exelixis, Inc. | COM | 30161Q104 | — | 2,835,000 shares | $67,473,000 |
| Akcea Therapeutics, Inc. | COM | 00972L107 | — | 2,377,638 shares | $67,358,000 |
| Myokardia Inc. | COM | 62857M105 | — | 1,264,913 shares | $65,763,000 |
| MacroGenics Inc. | COM | 556099109 | — | 3,400,000 shares | $61,132,000 |
| Wave Life Sciences Ltd. | SHS | Y95308105 | — | 1,465,002 shares | $56,915,000 |
| Voyager Therapeutics, Inc. | COM | 92915B106 | — | 2,865,841 shares | $54,852,000 |
| Audentes Therapeutics, Inc. | COM | 05070R104 | — | 1,369,604 shares | $53,442,000 |
| Alder Biopharmaceuticals Inc. | COM | 014339105 | — | 2,766,008 shares | $37,756,000 |
| Crispr Therapeutics AG | NAMEN AKT | H17182108 | — | 810,462 shares | $28,950,000 |
| Scholar Rock Holding Corp | COM | 80706P103 | — | 1,476,839 shares | $27,750,000 |
| Intra-Cellular Therapies, Inc. | COM | 46116X101 | — | 2,200,000 shares | $26,796,000 |
| Sangamo Therapeutics, Inc | COM | 800677106 | — | 2,650,000 shares | $25,281,000 |
| Kezar Life Sciences, Inc. | COM | 49372L100 | — | 1,220,503 shares | $21,652,000 |
| G1 Therapeutics, Inc. | COM | 3621LQ109 | — | 671,925 shares | $11,154,000 |
| Cidara Therapeutics, Inc. | COM | 171757107 | — | 2,295,272 shares | $6,082,000 |
| Novavax Inc. | COM | 670002104 | — | 8,330,000 shares | $4,589,000 |
| Homology Medicines, Inc. | COM | 438083107 | — | 91,336 shares | $2,533,000 |